Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes

Biomolecules. 2022 Dec 30;13(1):75. doi: 10.3390/biom13010075.

Abstract

The tumor microenvironment has recently emerged as a critical component of high-grade serous ovarian cancer (HGSC) disease progression. Specifically, cancer-associated fibroblasts (CAFs) have been recognized as key players in various pro-oncogenic processes. Here, we use mass-spectrometry (MS) to characterize the proteomes of HGSC patient-derived CAFs and compare them to those of the epithelial component of HGSC to gain a deeper understanding into their tumor-promoting phenotype. We integrate our data with primary tissue data to define a proteomic signature of HGSC CAFs and uncover multiple novel CAF proteins that are prognostic in an independent HGSC patient cohort. Our data represent the first MS-based global proteomic characterization of CAFs in HGSC and further highlights the clinical significance of HGSC CAFs.

Keywords: N-glycoproteomics; cancer-associated fibroblast; high-grade serous ovarian cancer; mass spectrometry; proteomics; tumor microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Cancer-Associated Fibroblasts* / metabolism
  • Carcinoma, Ovarian Epithelial
  • Cystadenocarcinoma, Serous* / genetics
  • Cystadenocarcinoma, Serous* / metabolism
  • Cystadenocarcinoma, Serous* / pathology
  • Female
  • Humans
  • Ovarian Neoplasms* / metabolism
  • Proteomics
  • Tumor Microenvironment

Substances

  • Biomarkers, Tumor

Grants and funding